BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (NASDAQ:BCDA) will host a conference call on Wednesday, August 12, 2026 at 4:30 PM EDT to provide a corporate update and report its Q2 2026 financial results. The event will include prepared remarks followed by a question-and-answer session.
Participants can register online to receive dial-in details or join by phone at 1-833-316-0559 (U.S.) or 1-412-317-5730 (international). A live webcast and both webcast and telephonic replays will be available, with webcast replay access through approximately November 12, 2026.
Details
News Market Reaction – BCDA
On Aug 5, the day this news came out, BCDA closed 4.37% above the previous close. Argus tracked a peak move of +3.1% during that session. Our momentum scanner recorded 8 alerts for this stock that day. That session’s volume was 2.3x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Aug 5 session.
Key Figures
- Reporting period
- Q2 2026
- Financial results to be reported
- Conference call date
- August 12, 2026
- Scheduled corporate update and results call
- Conference call time
- 4:30 PM EDT
- Scheduled start time
Previous Conferences,earnings date Reports
-
Q1 2026 results and corporate update call scheduled for May 15
-
2025 financial results and corporate update call scheduled for March 24
-
Q3 2025 corporate update and financial results call scheduled for November 12
-
Q2 2025 corporate update and financial results call scheduled for August 11
-
Q1 2025 corporate update and financial results call scheduled for May 14
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to: https://dpregister.com/sreg/10211154/104a4f51d2e.
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ufQzaenK.
A webcast replay of the call will be available approximately one hour after the end of the call through approximately November 12, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 3063624.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart 3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biological therapies. For more information visit www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.